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Abstract 
Objective: Observational studies have suggested positive associations between serum 25-
hydroxyvitamin D (25(OH)D) levels and muscular strength, balance and quality of life.  Our aim was to 
examine whether high-dose vitamin D supplementation would improve these measures as compared 
to standard-dose vitamin D, as well as the possible muscular effects of Single Nucleotide 
Polymorphisms (SNPs) in genes encoding vitamin D-related enzymes.  
Design: A 12-month randomized, double-blind, controlled trial where the participants received daily 
elemental calcium (1,000 mg) plus vitamin D3 (800 IU). In addition, the participants were randomized 
to receive either capsules with vitamin D3 (20,000 IU) or matching placebos to be taken twice a week. 
Patients: 297 postmenopausal women with osteopenia or osteoporosis.  
Measurements: Muscle strength (handgrip and knee extensor strength), balance (tandem test) and 
quality of life (EQ-5D) were measured at baseline and after 12 months. The subjects were genotyped 
for SNPs related to vitamin D metabolism.  
Results: Of the 297 included women, 275 completed the study. Mean serum 25(OH)D levels 
dramatically increased in the high-dose group (from 64.7 to 164.1 nmol/l; p<0.01), while a more 
moderate increased was observed in the standard-dose group (from 64.1 to 81.8 nmol/l; p<0.01). 
There was no significant difference between the groups in change in muscular strength, balance or 
quality of life over the intervention period. Polymorphisms in rs3829251 (located in the 7-
dehydrocholesterol reductase gene) was associated with muscle strength and treatment effects. 
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Conclusion: One-year treatment with high-dose vitamin D had no effect on muscular strength, 
balance or quality of life in postmenopausal women with osteopenia or osteoporosis as compared to 
standard-dose. The association between rs3829251 and muscle strength needs confirmation in other 
populations.   
 
Introduction 
The effects of vitamin D on calcium homeostasis and its importance for skeletal health are well-
known 1. In recent times, there has been an increased focus on non-skeletal effects of vitamin D, 
following the discovery of vitamin D receptors (VDRs) and the vitamin D activating enzyme 1-alfa-
hydroxylase in extraskeletal tissues 2. Observational studies have reported associations between 
higher serum 25-hydroxyvitamin D (25(OH)D) levels and lower risk of multiple pathological 
conditions2. It is of note, however, the general lack of data from randomized controlled trials (RCTs) 
confirming the positive effects hypothesized from the descriptive studies 2; 3 . 
There has been conflicting data regarding the presence of VDR in muscle cells, which may be 
explained by different laboratory approaches.  VDRs were detected in mice muscle cells by using 
highly specific antibodies in combination with a hyperosmolar lysis buffer able to release VDR bound 
to DNA 4. In addition, the expression of VDR was higher in younger than in adult mice, and more 
pronounced in muscle cells precursors than in mature muscle cells, expression trends that were 
previously reported for human muscle cells 4; 5 
In observational studies, muscle strength and balance have been associated with serum 
25(OH)D levels 6; 7.  A recent systematic review and meta-analysis reported a weak positive benefit of 
vitamin D intervention on global muscle strength, with a stronger benefit in adults with baseline 
serum 25(OH)D levels < 30 nmol/l, and also in participants aged > 65 years 8. In addition, a 11% 
reduction in falls was reported in a separate recent meta-analysis of RCTs, with the effect stronger in 
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those with baseline 25(OH)D levels <75 nmol/l 9. However, these results must be interpreted in light 
of the heterogeneity in types and dosing regimens of vitamin D interventions.  The RCTs have also 
used a variety of different assays for assessment of serum 25(OH)D and there are well-reported 
method-related differences in serum 25(OH)D estimates 10, which may also be confounding some of 
the meta-analyses, especially when thresholds are applied. Recently, concern has been raised 
regarding adverse effects on risk of falling in studies using high-dose vitamin D 11.  
Several studies have reported associations between different single nucleotide 
polymorphisms (SNPs) in the VDR and muscle strength 12; 13; 14. So far, this has not been addressed in 
a RCT setting, and whether different SNPs could affect the results of vitamin D intervention on 
muscle strength is therefore unknown.  
Quality of life could be regarded an integrative measure of self-perceived health. This should 
be highly relevant in the context of the possible pleiotropic effects of vitamin D, where quality of life 
could be considered a composite endpoint integrating various health effects of vitamin D. 
Observational studies have reported positive associations between serum 25(OH)D levels and quality 
of life 15; 16.  The results from intervention studies are, however, conflicting 17; 18; 19; 20.  
In 2007-2009, we performed a vitamin D supplementation RCT in postmenopausal women 
with changes in bone mineral density as the primary endpoint 21. When planning the study, we 
hypothesised that a higher dose of vitamin D would be more efficient than a standard dose, and we 
therefore compared two different doses of vitamin D3 co-administrated with calcium. In the present 
work, we present the results in relation to the secondary outcomes muscle strength, balance and 
self-reported quality of life, which may be of importance in the on-going discussion on possible 
detrimental effects of high-dose vitamin D. As the participants were genotyped for SNPs in genes 
related to vitamin D metabolism 22, we also had the possibility to study whether vitamin D 
supplementation affected muscle strength differently on the basis of genotype.  
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Materials and methods 
Study population 
The study population consisted of 297 postmenopausal women aged 50-80 years with a bone 
mineral density T-score of ≤ -2.0 in either lumbar spine (L2.4) or total hip as measured by dual X-ray 
absorptometry (DEXA). The women were recruited through a number of means, including through 
advertisement, through other studies where bone mineral density was measured, or through the 
outpatient clinic at the University Hospital of North Norway, see flow chart (Fig. 1). The inclusion 
procedure is described in detail elsewhere 21. Exclusion criteria were use of antiresorptive therapy or 
hormonal replacement therapy less then 12 months prior to the study, use of steroids, renal stone 
disease, coronary heart disease, cancer, diabetes, granulomatous disease, hypertension (as defined 
by systolic blood pressure > 175 mmHg or diastolic blood pressure > 105 mmHg), renal failure (as 
defined by serum creatinine > 110 µmol/l), hypercalcemia (as defined as serum calcium > 2.55 
mmol/l), or suspected primary hyperparathyroidism (as defined by serum calcium > 2.50 mmol/l 
combined with plasma parathyroid hormone (PTH) levels > 5.0 pmol/l or serum calcium > 2.45 
mmol/l combined with plasma PTH > 7.0 pmol/l.)  
 
Protocol 
The participants were screened with a questionnaire, followed by a physical examination including 
DEXA, and blood sampling. Those who met the inclusion criteria and signed the informed consent, 
were invited to a first visit where participants were requested to cease any ongoing calcium or 
vitamin D supplementation. All the participants then received a daily dose of 1000 mg calcium plus 
800 IU vitamin D3 (Calcigran Forte
®). In addition, they were randomized to either capsules containing 
20 000 IU vitamin D3 (the high-dose group) or similar-looking placebo capsules (the standard-dose 
group) to be taken twice a week. This constituted an average daily dose of 6500 IU vitamin D3 in the 
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high-dose group and 800 IU vitamin D3 in the standard-dose group. The randomization was 
performed by the central randomization unit at the University Hospital of North Norway using block 
randomization with various block sizes, stratified by smoking (yes/no) and previous bisphosphonate 
use (yes/no). The randomization numbers with treatment allocation were given directly to the 
hospital pharmacy who prepared the medication boxes, which were then given to the study nurse at 
the baseline visit, ensuring blinding for the participants, the study nurses and the researchers 
involved in the RCT.  
The intervention period lasted for 1 year with visits every 3 months on which occasions, 
blood sampling, registration of adverse effects and counting of returned study medication were 
performed. The study was approved by the Regional Committee for Medical Research Ethics, the 
Norwegian Data Inspectorate and the Norwegian Medicines Agency. The study was registered at 
ClinicalTrials.gov (NCT 00491920). The participants signed a written consent before inclusion. They 
could refuse the genotyping and still enter the main study, which two participants chose to do.  
 
Measurements 
Physical examinations 
All the measurements were performed at the Research Unit at the University Hospital of 
North Norway, Tromsø, by trained research technicians. This well-established research unit had 
previous experience with muscle testing 23, and underwent extensive training ahead of the start of 
the RCT. Where possible, the same technician performed both baseline and follow-up tests in the 
same participant, but due to logistic reasons, this was not feasible in all cases. 
Handgrip strength was measured using a Martin vigorimeter (Elmed Inc., Addison, IL, USA). 
For both the dominant and non-dominant hand, the best result out of three tests, with at least 15 
seconds break between each test, was noted.  Knee extensor strength was measured by knee 
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extension of the dominant leg (peak torque) using a NORM dynamometer (CSMI, Norwood, MA, 
USA). Each test for knee extensor strength consisted of five repetitions with submaximal extension 
and flexion at 90 °/second followed by one minute of rest and thereafter five maximal repetitions at 
90 °/second. As the producer listed osteoporosis as a relative contraindication towards performing 
the test, this measurement was restricted to those with osteopenia (T-score > -2.5). Balance was 
assessed using tandem test, where the participants were asked to stand with their feet in three 
different positions as shown in figure 2, each for 10 seconds. Points were given equal to the time in 
seconds when the correct position was maintained (without needing support or losing the balance), 
resulting in a maximum score of 30 points. Body height and weight were measured without shoes 
and with light clothing at baseline and 12 months. 
 
Questionnaires 
 The participants self-completed in the EuroQol five dimensions (EQ-5D)/three levels 
questionnaire, including a visual analogue score (VAS) of perceived health, at baseline and 12 
months. A EQ-5D index score, based on values derived from a large population-based sample from 
the UK 24, was calculated according to the user manual 25. A food-frequency questionnaire was also 
self-completed at baseline, and the intakes of vitamin D and calcium were calculated 26.  The 
International Physical Activity Questionnaire (IPAQ), (short, last 7 days, self-administered format) was 
also completed at baseline, and the amount of physical activity was calculated based on reported 
light, moderate and vigorous activities, and reported as units of metabolic equivalents (MET)-
min/week, in accordance with the IPAQ guidelines. The participants were then classified according to 
the IPAQ groups inactive, minimally active or health-enhancing physically active 27. 
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Biochemical measurements 
 Non-fasting blood samples were taken and processed to serum, which was subsequently 
aliquoted and stored at -70◦C for later analyses. Serum 25(OH)D was originally analysed at the 
Hormone Laboratory, Haukeland University Hospital, using an in-house developed liquid 
chromatography double mass spectrometry method 28. The between-day precision was ≤ 8.7%. 
However, in order to standardize our results and make them comparable across different studies and 
countries, we recently re-analyzed our stored samples from baseline and 12 months using the LC-
MS/MS method at the Cork Centre for Vitamin D and Nutrition Research, which is certified by the 
Centers for Disease Control and Prevention’s Vitamin D Standardization-Certification Program 
(VDSCP)10. In addition to being a participant in VDSCP, the laboratory is monitored on an on-going 
basis by participation in the Vitamin D External Quality Assessment Scheme (DEQAS) (Charing Cross 
Hospital, London, UK). These standardized 25(OH)D results will be used in the present paper. 
All genotyping was performed by KBioscience (http://www.kbioscience.co.uk) using KASP 
SNP genotyping system. KASP is a competitive allele-specific PCR incorporating a FRET quencher 
cassette. The SNPs were originally selected based on their reported associations with serum 25(OH)D 
levels 22. Thus, the following SNPs were included in the present analyses: rs2282679 at the DBP gene, 
the rs10741657 at the 25-hydroxylase/CYP2R1 gene, and rs3829251 at the 7-dehydrocholesterol 
reductase /NAD synthetase 1 gene. In addition, the 4 most important polymorphisms in the VDR 
(BsmI (rs1544410), TaqI (rs731236), ApaI (rs7975232), FokI (rs2228570) were also included. 
 
Statistical analyses 
 We used the statistical software package SPSS version 22 for the present analyses. 
Descriptive results are shown as mean (SD), unless otherwise stated. Independent t-tests or chi 
square tests were used for between-groups comparisons, and paired t-tests were used to assess 
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changes within each treatment group. Subgroup effects were studied in predefined strata of 
below/above median baseline serum 25(OH)D and PTH and age below/above 65 years. One-way 
ANOVA followed by Bonferroni correction was used for comparing muscle strength related to 
different genotypes. Regression analyses with an interaction term was used to assess statistical 
interaction between SNPs and the effect of treatment group on muscle strength. A P value < 0.05 
was regarded as statistically significant.  
 
Power calculations 
The power calculations were based on changes in the primary endpoint bone mineral density, as 
published previously 21. However, with the present sample size, the study had 80% power to detect a 
difference in the change in handgrip strength of 3.5 kPa between the treatment groups, given a SD of 
10 kPa and an alfa value of 0.05.  
 
Results 
Adherence and side effects 
Based on pill count data for those participants completing the study, the adherence was calculated to 
97% for the study medication and 92% for Calcigran Forte®. Side effects were not different between 
the two groups, and are reported in detail elsewhere 21. Of note, there was no difference in 
occurrence of urolithiasis or fractures. Falls were not specifically assessed in the present study. In 
relation to biochemical indices, the decrease in PTH was significantly greater, while the increments in 
1,25(OH)2D, serum calcium and urinary calcium/creatinine ratio were significantly greater in the high-
dose vitamin D group as compared to the standard-dose vitamin D group 21.   
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Results of the secondary outcome measures 
Table 1 shows the baseline characteristics of the participants. There were no statistical significant 
differences between the treatment groups. Delta values during the study for each treatment group 
are shown in Table 2.  Mean serum 25(OH)D increased significantly in both groups (P<0.01 for both), 
but the increment was substantially greater (P<0.01) in the high-dose group. There were no 
significant differences (P>0.2 for all) between the high- and standard-dose groups with respect to any 
of the other variables relating to muscle strength or quality of life. The change in proportion who 
scored less than maximum at the tandem test did not differ between the treatment groups (P=0.77). 
The results were similar in analyses stratified by median 25(OH)D or PTH, or age above/below 65 
years (data not shown). Table 3 shows the distribution of SNPs and the association with muscle 
strength at baseline. Those being major homozygote (GG) at the rs3829251 in the 7-
dehydrocholesterol reductase /NAD synthetase 1 gene had significantly better grip strength at the 
dominant (P<0.05) and non-dominant (P<0.01) hands. There was also a significant interaction 
between treatment group and the genotypes at this SNP (P for interaction 0.04) in relation to change 
in handgrip strength of the non-dominant side. Thus, in the minor homozygote group (AA), handgrip 
strength decreased in the high-dose vitamin D group (by -5.8 kPa), while it increased (by 7.2 kPa) in 
the standard-dose group, the difference being statistically significant at P=0.02 (Table 4). However, it 
should be noted that the group sample sizes were small. SNPs in other vitamin D-related genes did 
not appear to interact with the effect of vitamin D intervention on change in muscle strength (data 
not shown).  
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Discussion 
 In this 12-month RCT in postmenopausal women with poor bone health, there was no 
significant difference in muscle strength, balance or quality of life between the group randomized to 
the high-dose vitamin D3 supplementation regimen (6,500 IU/day on average) and that receiving 
standard-dose vitamin D3 (800 IU/day), both regimens co-administered with calcium. 
The strengths of this study were the size of the study, the high completion rate and the high 
adherence to the study medication. The doses of vitamin D used were sufficient to provide for a 
substantial rise in serum 25(OH)D as confirmed by measurements made with a CDC-certified LC-
MS/MS method. The outcome measures were validated, and included both upper and lower 
extremity strength as well as proximal and distal muscle performance. In addition, the EQ-5D 
questionnaire is validated in a wide range of conditions, although it should be noted that it has been 
subsequently refined by including five instead of three levels of answer alternatives.  
 Because the measurement of knee extensor strength was restricted to those with 
osteopenia and not osteoporosis, we had less power to assess proximal strength, and this was a 
limitation both in the main and subgroup analyses.  
The interpretation of the results was also limited by the fact that the majority of study 
participants were of adequate vitamin D status even at inclusion to the study.  For example, only 4 
and 24% had baseline serum 25(OH)D levels < 30 and < 50 nmol/l, respectively, and 30% had baseline 
25(OH)D levels > 75 nmol/l. Accordingly, these results align closely with the findings from most 
recently published meta-analyses on the effect of vitamin D on muscular strength, where the positive 
effect was significant only evident in those with baseline serum 25(OH)D levels <30 nmol/l 8. The 
results from the present RCT may also support the findings from observational studies which show 
the inverse association between vitamin D status and muscular strength plateaus when serum 
25(OH)D levels exceed 40 nmol/l 7.  In contrast, there are observational data to show that the OR for 
having sarcopenia in Korean women aged 50 years and older increased not only in vitamin D 
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deficiency (as defined as serum 25(OH)D < 37.5 nmol/l) but also in the range 37.4 – 75 nmol/l as 
compared to > 75 nmol/l 29.   However, ethnic differences in vitamin D metabolism as well as in 
associations between vitamin D status and different health outcomes have been reported 30, and 
thus, our results are restricted to Caucasian women only.  
 Of importance, there was no evidence of negative effects of high-dose as compared to 
standard-dose vitamin D supplementation, except for a minor increase in serum and urinary calcium 
of uncertain clinical importance. Unfortunately, falls were not specifically assessed in our study. In 
most of the clinical trials reporting detrimental effects of high-dose vitamin D on falls and fractures, 
vitamin D was administered by infrequent (monthly or yearly) bolus dosing 11. It has been speculated 
whether such high doses upregulate the expression of 24-hydroxylase, which will increase the 
deactivation of the active metabolite 1,25-dihydroxyvitamin D and consequently lower its levels 11. In 
addition, such a dosing regimen will lead to large fluctuations in the levels of the short-living mother 
compound cholecalciferol, which might affect intracellular vitamin D metabolism 31. Clearly, this issue 
needs further exploration 31. 
 
The tandem test chosen to evaluate balance in the present study turned out to be less useful 
in this healthy population, where the majority achieved maximum score already at baseline. Thus, 
this instrument did not discriminate balance sufficiently, and it is worth noting that other studies 
using body sway measurements have reported 28% improvement in body sway when vitamin D and 
calcium was given for 12 months as compared to calcium alone 32. In a systematic review, four out of 
eight randomized trials using vitamin D reported improvement in body sway 33. Furthermore, of 
those studies reporting an improvement, all had low serum 25(OH)D as an inclusion criteria 33.  
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 High-dose vitamin D did supplementation not improve quality of life as compared to 
standard-dose.  This is in accordance with other studies in elderly community-living participants 19; 20, 
and in heart failure patients 34. However, other studies have reported improvement in quality of life 
in patients with irritable bowel syndrome 17 as well as in patients with Crohn’s disease, the latter in 
an uncontrolled trial 18.  
As previous reports have demonstrated an influence by SNPs in the VDR gene on muscle 
strength 12; 13; 14, we performed analyses stratified by these SNPs as well as SNPs in genes encoding 
central enzymes in the vitamin D metabolism pathways. There was some evidence, both in cross-
sectional analyses at baseline, and in the results after intervention, that SNPs at rs3829251 affected 
the relationship between vitamin D and muscle strength.  These  SNPs are contained within the gene 
coding for 7-dehydrocholesterol reductase, an enzyme central in the UVB-induced production of 
previtamin D in the skin. Thus, those being major homozygote had a greater grip strength than those 
being heterozygote or minor homozygote, and within the minor homozygote subgroup, muscle 
strength increased in the standard-dose vitamin D group, while it decreased in the high-dose vitamin 
D group. This was not consistent at all muscle measurement sites, the groups were of small sample 
size, and the analyses were not adjusted for multiple comparisons. In light of multiple testing, our 
results could therefore represent random findings, and thus would need to be confirmed in other 
studies. We are not aware of any previous studies analysing this SNP in relation to muscle strength. 
Interestingly, we could not reproduce the previously reported associations between SNPs in 
the VDR and muscle strength. It should be noted that the groups with minor homozygotes in general 
were of small sample size, and type II errors can therefore not be excluded. Also, the high baseline 
vitamin D status might have obscured possible effects of genetic polymorphisms.    
 This study was designed to compare two doses of supplemental vitamin D, and not to assess 
the effect of vitamin D itself. The results of this study do not provide support for using high-dose 
vitamin D supplements in already vitamin D-replete subjects in terms of improving muscular 
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strength, balance, or quality of life. There were, however, no indications of harmful clinical effects, 
although a minor increase in serum and urinary calcium was noted, and the safety assessment was 
limited by the fact that falls were not specifically assessed. Clearly, the safety of long-term use of 
high-dose vitamin D could not be assessed from this one-year trial. Future studies should include 
vitamin D deficient participants only, and fall assessment should be included as an outcome measure 
in all high-dose vitamin D trials.  
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Fig. 1. Flow chart of study participants 
 
Fig 2. Tandem test 
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Table 1. Baseline characteristics 
  
High dose vitamin D 
(n=149) 
 
Standard dose vitamin D 
(n=148) 
 
Age (years) 62.8±7.4 63.4±6.9 
Age since menopause (years) 14.0±8.5 14.8±8.9 
BMI (kg/cm2) 24.9±3.4 24.6±3.3 
Serum 25(OH)D (nmol/l) 64.7±21.4 64.1±20.0 
Estimated vitamin D intake (mcg/day) 9.1±6.3 8.2±6.1 
Estimated calcium intake (mg/day) 797±313 823±335 
MET-min/week 3165±3207 3205±3504 
Physical activity (IPAQ)   
   Inactive 21.7 24.8 
   Minimally active 41.9 41.9 
   Health enhancing physically active 36.4 33.3 
Proportion smokers (%) 22.2 24.3 
Proportion with osteoporosis (%) 58 47 
Grip strength dominant hand (kPa) 54.9±16.4 53.5±14.4 
Grip strength non-dominant hand (kPa) 51.8±17.7 51.3±15.7 
Knee extensor strength (Nm) 72.7±16.2 70.8±15.7 
Tandem test, proportion scoring less than 
full score (%) 
9 13 
VAS of perceived health 81.4±13.0 81.4±14.0 
EQ-5D index 0.85±0.18 0.86±0.14 
EQ-5D - Mobility (%)   
   No problem walking 86.7 83.6 
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   Some problems walking 13.3 16.4 
   Confined to bed 0 0 
EQ-5D - Self-Care (%)   
   No problems with self-care 97.8 100 
   Some problems with self-care 2.2 0 
   Unable to wash or dress 0 0 
EQ-5D - Usual activities (%)   
   No problems 88.1 86.4 
   Some problems 11.9 13.6 
   Unable to perform usual activities 0 0 
EQ-5D - Pain/Discomfort (%)   
   No pain or discomfort 51.1 50.0 
   Moderate pain or discomfort 46.7 49.3 
   Extreme pain or discomfort 2.2 0.7 
EQ-5D - Anxiety/Depression (%)   
   Not anxious or depressed 83.0 80.7 
   Moderately anxious or depressed 17.0 19.3 
   Extremely anxious or depressed 0 0 
BMI, body mass index; EQ-5D, Euroqual 5 dimensions; MET, metabolic equivalents; VAS visual 
analogue scale; 25(OH)D, 25-hydroxyvitamin D 
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Table 2. Change in serum 25(OH)D, muscle strength and quality of life after intervention with 
standard or high dose vitamin D and calcium 
  
High dose vitamin D 
 
 
Standard dose vitamin D 
 
P for difference between 
groups 
 
 Serum 25(OH)D 
(nmol/l) 
99.4±31.9a 17.7±16.9a <0.01 
Grip strength 
dominant hand (kPa) 
0.1±9.4 0.7±8.0 0.59 
Grip strength non-
dominant hand (kPa) 
1.4±9.7 1.5±10.0 0.94 
Knee extensor 
strength (Nm)b 
-1.4±7.6 0.5±8.0 0.24 
VAS -1.5±12.8 -1.8±12.1 0.84 
EQ-5D index -0.02±0.16 -0.02±0.17 0.85 
 change from 12-months minus baseline value; EQ-5D, Euroqual 5 dimensions; VAS visual analogue 
scale; 25(OH)D, 25-hydroxyvitamin D 
achange from baseline, p<0.01 
b available measurements in 46 in the high dose and 59 in standard dose group 
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Table 3. Distribution of SNPs and correlation with muscle strength  
 
SNP 
 
genotype 
 
n 
 
Grip strength 
dominant 
side (kPa) 
 
 
P 
 
n 
 
Grip strength 
non-dominant 
side (kPa) 
 
P 
 
n 
 
Knee 
extensor 
strength 
(Nm) 
 
P 
                                                                  
 
Rs2282679 AA 164 53.6 (51.5-
55.6) 
0.83 162 51.0 (48.5-
53.5) 
0.76 78 73.0 (69.3-
76.7) 
0.17 
 AC 113 54.7 (51.7-
57.8) 
 112 51.9 (48.9-
54.9) 
 36 66.9 (62.2-
71.5) 
 
 CC 13 54.0 (38.8-
69.2) 
 13 54.2 (40.5-
67.8) 
 7 70.9 (54.2-
87.5) 
 
Rs10741657 GG 93 54.5 (51.7-
57.3) 
0.58 92 52.0 (48.5-
55.4) 
0.62 45 71.9 (67.4-
76.5) 
0.52 
 GA 144 53.1 (50.4-
55.8) 
 144 50.5 (47.8-
53.3) 
 57 69.4 (64.7-
74.1) 
 
 AA 55 55.4 (51.5-
59.4) 
 53 52.9 (48.9-
57.0) 
 19 73.8 (68.1-
79.5) 
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Rs3829251 GG 166 56.0 (53.6-
58.3) 
<0.05 165 54.2 (51.8-
56.7) 
<0.01* 64 73.0 (69.4-
76.6) 
0.35 
 GA 98 51.5 (48.4-
54.7) 
 96 47.1 (43.7-
50.6) 
 41 69.1 (63.3-
75.0) 
 
 AA 27 50.4 (45.6-
55.3) 
 27 49.4 (44.1-
54.7) 
 16 68.1 (60.7-
75.6) 
 
Rs1544410 GG 98 54.8 (51.7-
57.9) 
0.48 96 52.3 (48.8-
55.8) 
0.24 45 72.4 (67.6-
77.1) 
0.60 
 GA 139 52.8 (50.3-
55.3) 
 139 49.8 (47.1-
52.5) 
 51 69.3 (64.5-
74.2) 
 
 AA 53 55.2 (50.8-
59.5) 
 53 54.0 (49.9-
58.1) 
 25 72.2 (66.8-
77.5) 
 
Rs731236 TT 94 53.9 (50.9-
56.8) 
0.73 92 51.7 (48.1-
55.2) 
0.29 44 71.7 (67.0-
76.4) 
0.82 
 TC 136 53.2 (50.7-
55.8) 
 135 49.9 (47.1-
52.6) 
 50 70.1 (65.4-
74.8) 
 
 CC 53 55.1 (50.8-
59.4) 
 53 53.9 (49.8-
58.0) 
 25 72.2 (66.8-
77.5) 
 
Rs7975232 AA 104 53.5 (50.4-
56.5) 
0.07 103 51.6 (48.4-
54.8) 
0.19 41 71.6 (67.0-
76.2) 
0.13 
 CA 133 52.6 (50.2-
54.9) 
 132 49.8 (47.0-
52.5) 
 52 68.1 (63.4-
72.8) 
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 CC 53 58.3 (53.5-
63.1) 
 52 54.6 (50.0-
59.2) 
 28 75.6 (69.7-
81.5) 
 
Rs2228570 CC 109 53.0 (50.0-
55.9) 
0.39 107 50.5 (47.4-
53.5) 
0.44 46 70.4 (66.4-
74.5) 
0.44 
 TC 139 55.3 (52.9-
57.7) 
 139 52.7 (49.9-
55.4) 
 56 70.1 (65.4-
74.8) 
 
 TT 41 52.6 (47.0-
58.2) 
 40 49.7 (44.3-
55.0) 
 19 75.3 (67.6-
83.0) 
 
*Statistically significant different between GG and GA also after Bonferroni correction 
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Table 4. Change in muscle strength after intervention with standard or high dose vitamin D and calcium stratified by genotypes in rs3829251 
   
Hand grip dominant side  
 
Hand grip non-dominant side  
 
 
Knee extensor strength 
 
n 
 
 
change (kPa) 
 
n 
 
change (kPa) 
 
n 
 
change (Nm) 
 
GG High dose vitamin D  72 0.8 71 1.6 24 -2.4 
Standard dose vitamin D  82 0.3 83 0.8 31 -0.4 
GA High dose vitamin D  50 0.1 48 2.8 19 -1.1 
Standard dose vitamin D  39 -0.3 38 0.5 16 2.3 
AA High dose vitamin D 10 -4.5 10 -5.8 * 3 5.3 
Standard dose vitamin D 15 3.1 15 7.2 10 -1.5 
* P for difference <0.05 
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